EP3708173C0 - Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs - Google Patents

Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs

Info

Publication number
EP3708173C0
EP3708173C0 EP18876388.2A EP18876388A EP3708173C0 EP 3708173 C0 EP3708173 C0 EP 3708173C0 EP 18876388 A EP18876388 A EP 18876388A EP 3708173 C0 EP3708173 C0 EP 3708173C0
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
pharmaceutical composition
composition containing
containing mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18876388.2A
Other languages
English (en)
French (fr)
Other versions
EP3708173B1 (de
EP3708173A4 (de
EP3708173A1 (de
Inventor
Hidetoshi Tahara
Masaki Kinehara
Yuki Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purmx Therapeutics Inc
Original Assignee
Purmx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purmx Therapeutics Inc filed Critical Purmx Therapeutics Inc
Priority to EP23186136.0A priority Critical patent/EP4276183A3/de
Priority to EP23186139.4A priority patent/EP4276184A3/de
Priority to EP23186073.5A priority patent/EP4265725A3/de
Publication of EP3708173A1 publication Critical patent/EP3708173A1/de
Publication of EP3708173A4 publication Critical patent/EP3708173A4/de
Application granted granted Critical
Publication of EP3708173B1 publication Critical patent/EP3708173B1/de
Publication of EP3708173C0 publication Critical patent/EP3708173C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Botany (AREA)
EP18876388.2A 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs Active EP3708173B1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP23186136.0A EP4276183A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186139.4A EP4276184A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186073.5A EP4265725A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017216336 2017-11-09
PCT/JP2018/041139 WO2019093308A1 (ja) 2017-11-09 2018-11-06 ｍｉＲＮＡを含むがん治療用医薬組成物

Related Child Applications (6)

Application Number Title Priority Date Filing Date
EP23186073.5A Division-Into EP4265725A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186073.5A Division EP4265725A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186139.4A Division-Into EP4276184A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186139.4A Division EP4276184A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186136.0A Division EP4276183A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186136.0A Division-Into EP4276183A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs

Publications (4)

Publication Number Publication Date
EP3708173A1 EP3708173A1 (de) 2020-09-16
EP3708173A4 EP3708173A4 (de) 2022-03-02
EP3708173B1 EP3708173B1 (de) 2023-09-13
EP3708173C0 true EP3708173C0 (de) 2023-09-13

Family

ID=66437770

Family Applications (4)

Application Number Title Priority Date Filing Date
EP18876388.2A Active EP3708173B1 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186136.0A Pending EP4276183A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186139.4A Pending EP4276184A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186073.5A Pending EP4265725A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP23186136.0A Pending EP4276183A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186139.4A Pending EP4276184A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP23186073.5A Pending EP4265725A3 (de) 2017-11-09 2018-11-06 Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs

Country Status (9)

Country Link
US (3) US11311568B2 (de)
EP (4) EP3708173B1 (de)
JP (3) JP6651061B2 (de)
KR (3) KR20240158357A (de)
CN (4) CN111405901B (de)
AU (1) AU2018364916B2 (de)
CA (1) CA3083756A1 (de)
ES (1) ES2956776T3 (de)
WO (1) WO2019093308A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117085140A (zh) 2017-12-15 2023-11-21 立美基股份有限公司 表面活性剂肽纳米结构及在药物递送中的用途
CN112516317B (zh) * 2020-12-10 2021-12-17 暨南大学附属第一医院（广州华侨医院） 一种预防和治疗癌症的药物组合物及其应用
KR20220169178A (ko) 2021-06-18 2022-12-27 한국과학기술원 타겟 유전자 발현을 조절할 수 있는 헤어핀 구조의 핵산 분자 및 이의 용도
KR102897439B1 (ko) 2021-06-18 2025-12-08 한국과학기술원 타겟 유전자 발현을 조절할 수 있는 핵산 분자 및 이의 용도
JP7773257B2 (ja) 2022-03-28 2025-11-19 合同会社HiRoko Science ｍｉＲ－１４０を含む医薬組成物及びその製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5145557B2 (ja) 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
WO2008137862A2 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Methods of using mir34 as a biomarker for tp53 functional status
US9683232B2 (en) * 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
JP5116026B2 (ja) 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
SG193822A1 (en) 2008-08-27 2013-10-30 3 D Matrix Ltd Transfection agent
US8252059B2 (en) * 2008-12-17 2012-08-28 Synthes Usa, Llc Full-metal dampening intervertebral implant
JP2010222338A (ja) 2009-02-27 2010-10-07 Three D Matrix:Kk 核酸移送担体
EP2496714B1 (de) * 2009-11-04 2016-08-31 DiamiR, LLC Verfahren zur verwendung von micro-rna in körperflüssigkeiten zum nachweis und überwachung leichter kognitiver beeinträchtigung
US20120315640A1 (en) 2009-12-21 2012-12-13 Hidetoshi Tahara Senescence marker, method for evaluating senescence inhibitor, and cancer inhibitor
EP2518144B1 (de) 2009-12-21 2015-08-05 Hiroshima University Alterungsmarker, verfahren zur beurteilung eines alterungshemmer und krebshemmer
EP2772550B1 (de) * 2010-11-17 2017-03-29 Interpace Diagnostics, LLC MiRNA als Biomarker zur Unterscheidung zwischen benignen und malignen Thyroid-Neoplasien
SG192707A1 (en) 2011-02-11 2013-09-30 Univ Singapore Treating cancer by inhibiting expression of olfm4, sp5, tobi, arjdia, fbni or hat1
CA2874003A1 (en) * 2012-05-31 2013-12-05 Sotirios KOUTSOPOULOS Sustained delivery of molecules using peptide surfactants and uses thereof
WO2014081507A1 (en) * 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
ES2927175T3 (es) * 2013-02-12 2022-11-03 Reneuron Ltd Método de producción de micropartículas
WO2015020122A1 (ja) 2013-08-08 2015-02-12 国立大学法人 大阪大学 尿路上皮癌の診断または治療剤
RU2686313C2 (ru) * 2015-02-25 2019-04-25 Байонир Корпорейшн Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента

Also Published As

Publication number Publication date
EP4276183A3 (de) 2023-12-27
CN118615311A (zh) 2024-09-10
EP3708173B1 (de) 2023-09-13
JPWO2019093308A1 (ja) 2020-02-27
EP4276184A3 (de) 2023-12-27
EP4265725A2 (de) 2023-10-25
EP4276183A2 (de) 2023-11-15
EP3708173A4 (de) 2022-03-02
CA3083756A1 (en) 2019-05-16
CN111405901A (zh) 2020-07-10
EP3708173A1 (de) 2020-09-16
ES2956776T3 (es) 2023-12-27
US20200254001A1 (en) 2020-08-13
KR20240158356A (ko) 2024-11-04
JP6651061B2 (ja) 2020-02-19
CN118615312A (zh) 2024-09-10
US11311568B2 (en) 2022-04-26
WO2019093308A1 (ja) 2019-05-16
KR20240158357A (ko) 2024-11-04
AU2018364916B2 (en) 2024-05-23
US20220218733A1 (en) 2022-07-14
US12090167B2 (en) 2024-09-17
CN118615313A (zh) 2024-09-10
JP7360705B2 (ja) 2023-10-13
CN111405901B (zh) 2025-09-09
AU2018364916A1 (en) 2020-06-18
EP4276184A2 (de) 2023-11-15
US20220202848A1 (en) 2022-06-30
JP2020055886A (ja) 2020-04-09
KR20200085801A (ko) 2020-07-15
KR102751025B1 (ko) 2025-01-09
US12121535B2 (en) 2024-10-22
EP4265725A3 (de) 2023-12-27
JP2023165816A (ja) 2023-11-17

Similar Documents

Publication Publication Date Title
PL3717471T3 (pl) Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
EP3565558A4 (de) Kombinationstherapie zur behandlung von krebs
EP3471735A4 (de) Pharmazeutische zubereitungen und deren verwendung zur behandlung von krebs und autoimmunkrankheiten
EP3634417C0 (de) Chinazolin-pyrazolderivate zur behandlung von krebsbedingten erkrankungen
EP3995139C0 (de) Zusammensetzung zur behandlung von krebs
EP3263132C0 (de) Zusammensetzung zur behandlung von il-6-assoziierten erkrankungen
EP3684418C0 (de) Verbindungen zur behandlung von cysteaminempfindlichen erkrankungen
EP3581183A4 (de) Pharmazeutische zusammensetzung zur tumorbehandlung
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
EP3943093C0 (de) Verwendung von pasteurisierter akkermansia zur behandlung von krebs
EP3750530C0 (de) Kombinationen von irs/stat3-doppelmodulatoren und antikrebsmittel zur behandlung von krebs
EP3678663A4 (de) Kombinationstherapie zur behandlung von krebs
EP3377068C0 (de) Kombinationstherapie von tetracyclischen chinolonanalogen zur behandlung von krebs
EP3589289A4 (de) Hemmung von smarca2 zur behandlung von krebs
EP3925969C0 (de) Peptidverbindungen und peptidkonjugate zur behandlung von krebs durch rezeptorvermittelte chemotherapie
EP3673899C0 (de) Nasenpulverformulierung zur behandlung von hypoglykämie
EP3597208A4 (de) Pharmazeutische zusammensetzung mit atpif1 zur behandlung von diabetes
EP3915583A4 (de) Kombinierte pharmazeutische zusammensetzung zur tumorbehandlung
EP3359521C0 (de) Neuartige verbindungen zur behandlung von mitochondrienerkrankungen
EP3708173C0 (de) Pharmazeutische zusammensetzung enthaltend mirna-3140 zur behandlung von krebs
EP3621593C0 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von herz-kreislauf-erkrankungen
EP3572095A4 (de) Pharmazeutische zusammensetzung zur behandlung von mit htlv-1-assoziierter myelopathie
EP4151227A4 (de) Pharmazeutische zusammensetzung zur behandlung von krebs
EP3569238A4 (de) Zusammensetzung zur behandlung von neonataler hie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20211012BHEP

Ipc: A61P 43/00 20060101ALI20211012BHEP

Ipc: A61P 35/00 20060101ALI20211012BHEP

Ipc: A61K 47/46 20060101ALI20211012BHEP

Ipc: A61K 47/42 20170101ALI20211012BHEP

Ipc: A61K 45/00 20060101ALI20211012BHEP

Ipc: A61K 31/7088 20060101ALI20211012BHEP

Ipc: A61K 31/7105 20060101AFI20211012BHEP

REG Reference to a national code

Ref legal event code: R079

Ipc: A61K0031710500

Ref country code: DE

Ref legal event code: R079

Ref document number: 602018057694

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031708800

Ipc: A61K0031710500

A4 Supplementary search report drawn up and despatched

Effective date: 20220128

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20220124BHEP

Ipc: A61P 43/00 20060101ALI20220124BHEP

Ipc: A61P 35/00 20060101ALI20220124BHEP

Ipc: A61K 47/46 20060101ALI20220124BHEP

Ipc: A61K 47/42 20170101ALI20220124BHEP

Ipc: A61K 45/00 20060101ALI20220124BHEP

Ipc: A61K 31/7088 20060101ALI20220124BHEP

Ipc: A61K 31/7105 20060101AFI20220124BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PURMX THERAPEUTICS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230424

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018057694

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20230914

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20230922

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 6

Effective date: 20231031

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2956776

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231213

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240113

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018057694

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

26N No opposition filed

Effective date: 20240614

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 7

Effective date: 20241028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20181106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20181106

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251201

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 8

Effective date: 20251029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230913

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251121

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251201

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20251121

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251229

Year of fee payment: 8